Physician profile
Claire E Bareiss
NPI 1255735841
$3,812.68
in general payments reported to CMS, 2019-2025
34 companies · $1,371 in 2025
The $1,371 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $565 · 2022: $792 · 2023: $567 · 2024: $518 · 2025: $1,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,455.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $610.84 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $604.18 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $478.04 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.54 | 2021-2024 | Jardiance, Tradjenta |
| Mannkind Corporation | $145.04 | 2021-2025 | |
| Amgen INC. | $140.42 | 2021-2025 | Evenity, Prolia |
| Amneal Pharmaceuticals LLC | $131.28 | 2021-2025 | Unithroid |
| Corcept Therapeutics | $125.70 | 2022-2025 | Korlym |
| Abbott Laboratories | $115.04 | 2021-2025 | Freestyle Libre 3 |
| Organon LLC | $103.28 | 2025 | Nexplanon |
| Exeltis, USA INC. | $101.47 | 2025 | Slynd, Twirla |
| Medtronic, INC. | $99.98 | 2021-2022 | |
| Biogen, INC. | $80.13 | 2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $75.70 | 2025 | |
| Beta Bionics, INC. | $73.55 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $66.74 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $58.28 | 2023-2025 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $52.92 | 2022-2023 | Crysvita |
| Ibsa Pharma INC. | $51.79 | 2022-2025 | Tirosint, Flector, Licart |
| Xeris Pharmaceuticals, INC. | $49.42 | 2021-2022 | |
| Hologic Sales and Service, LLC | $49.27 | 2025 | Novasure, Myosure Tissue Removal Device |
| Ascendis Pharma Endocrinology INC | $48.83 | 2025 | Yorvipath |
| Exact Sciences Corporation | $46.17 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $36.48 | 2025 | Myfembree |
| Radius Health, INC. | $35.74 | 2025 | Tymlos |
| Ascensia Diabetes Care US INC. | $33.93 | 2023 | |
| Astellas Pharma US INC | $26.85 | 2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $24.09 | 2021 | |
| Dexcom, INC. | $23.50 | 2021 | |
| Merck Sharp & Dohme LLC | $21.13 | 2025 | Gardasil 9 |
| Alvogen INC | $20.00 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $19.65 | 2025 | |
| Coopersurgical, INC. | $19.07 | 2025 | Paragard T 380a |
| Esperion Therapeutics, INC. | $14.63 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Bareiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.